QuVa Pharma’s $275 Million Financing

Latham & Watkins LLP represented Goldman Sachs and Owl Rock in the financing.

QuVa Pharma, Inc., the leading national 503B outsourcing services company providing hospitals with essential medications in ready-to-administer injectable formats, has announced its latest financing, a US$275 million senior debt facility led by investment vehicles managed by the Goldman Sachs Private Credit Investing, with participation from Owl Rock Capital Partners, LP. The financing enables QuVa Pharma to meet the needs of its approximately 2,000 hospital customers, add more hospitals to the platform, and expand its 200 SKU product portfolio.

Latham & Watkins LLP represented Goldman Sachs and Owl Rock in the financing with a team led by New York partners Stelios Saffos (Picture) and Peter Sluka, with Houston counsel Bryce Kaufman and Houston associate Brian Flynn. Advice was also provided on tax matters by New York partner Jiyeon Lee-Lim and Houston partner Bryant Lee, with Houston associate Dominick Constantino; on FDA regulatory matters by Washington, D.C. associate Eitan Bernstein; and on environmental matters by Los Angeles/Washington, D.C. counsel Joshua Marnitz

Involved fees earner: Eitan Bernstein – Latham & Watkins; Dominick Constantino – Latham & Watkins; Brian Flynn – Latham & Watkins; Bryce Kaufman – Latham & Watkins; Bryant Lee – Latham & Watkins; Jiyeon Lee-Lim – Latham & Watkins; Joshua Marnitz – Latham & Watkins; Stelios Saffos – Latham & Watkins; Peter Sluka – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Goldman Sachs; Owl Rock Capital Advisors ;

Author: Martina Bellini

QuVa Pharma’s $275 Million Financing

Latham & Watkins LLP represented Goldman Sachs and Owl Rock in the financing.

QuVa Pharma, Inc., the leading national 503B outsourcing services company providing hospitals with essential medications in ready-to-administer injectable formats, has announced its latest financing, a US$275 million senior debt facility led by investment vehicles managed by the Goldman Sachs Private Credit Investing, with participation from Owl Rock Capital Partners, LP. The financing enables QuVa Pharma to meet the needs of its approximately 2,000 hospital customers, add more hospitals to the platform, and expand its 200 SKU product portfolio.

Latham & Watkins LLP represented Goldman Sachs and Owl Rock in the financing with a team led by New York partners Stelios Saffos (Picture) and Peter Sluka, with Houston counsel Bryce Kaufman and Houston associate Brian Flynn. Advice was also provided on tax matters by New York partner Jiyeon Lee-Lim and Houston partner Bryant Lee, with Houston associate Dominick Constantino; on FDA regulatory matters by Washington, D.C. associate Eitan Bernstein; and on environmental matters by Los Angeles/Washington, D.C. counsel Joshua Marnitz

Involved fees earner: Eitan Bernstein – Latham & Watkins; Dominick Constantino – Latham & Watkins; Brian Flynn – Latham & Watkins; Bryce Kaufman – Latham & Watkins; Bryant Lee – Latham & Watkins; Jiyeon Lee-Lim – Latham & Watkins; Joshua Marnitz – Latham & Watkins; Stelios Saffos – Latham & Watkins; Peter Sluka – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Goldman Sachs; Owl Rock Capital Advisors ;

Author: Martina Bellini